Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas. Hematology Meeting Reports (formerly Haematologica Reports), [S. l.], v. 2, n. 5, 2009. DOI: 10.4081/hmr.v2i5.749. Disponível em: https://journals.pagepress.org/hmr/article/view/749. Acesso em: 20 jun. 2025.